UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A20 Gene Deregulation In Waldenstrom's Macroglobulinemia

Blood, 2010-11, Vol.116 (21), p.3628-3628

2010

Volltextzugriff (PDF)

ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22 (Suppl.2), p.S358-S359

2022

Volltextzugriff (PDF)

ABCL-183 Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin (COO) in the POLARIX Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S460-S460

2024

Volltextzugriff (PDF)

Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy

Leukemia research, 2011, Vol.35 (11), p.e203-e205

2011

Volltextzugriff (PDF)

Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): Evolution on hypomethylating agent therapy

Leukemia research, 2011-11, Vol.35 (11), p.e203-e205

2011

Volltextzugriff (PDF)

Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma

Current research in translational medicine, 2018-09, Vol.66 (3), p.87-89

2018

Volltextzugriff (PDF)

Anti‐PD‐1 therapy can possibly reverse CAR T cells exhaustion in DLBCL

British journal of haematology, 2023-07, Vol.202 (2), p.217-218

2023

Volltextzugriff (PDF)

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8053-8053

2020

Volltextzugriff (PDF)

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.7544-7544

2021

Volltextzugriff (PDF)

B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenström Macroglobulinemia

Blood, 2012-11, Vol.120 (21), p.1288-1288

2012

Volltextzugriff (PDF)

B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenström Macroglobulinemia

Blood, 2012-11, Vol.120 (21), p.1288-1288

2012

Volltextzugriff (PDF)

BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia

Oncotarget, 2017-08, Vol.8 (34), p.57451-57459

2017

Volltextzugriff (PDF)

Bendamustine is effective in T‐Cell prolymphocytic leukaemia

British journal of haematology, 2015-03, Vol.168 (6), p.916-919

2015

Volltextzugriff (PDF)

Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)

British journal of haematology, 2019-07, Vol.186 (1), p.146-149

2019

Volltextzugriff (PDF)

The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Blood, 2017-12, Vol.130, p.4046-4046

2017

Volltextzugriff (PDF)

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

Frontiers in immunology, 2022-12, Vol.13

2022

Volltextzugriff (PDF)

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

Frontiers in immunology, 2022, Vol.13

2022

Volltextzugriff (PDF)

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

Frontiers in immunology, 2022-12, Vol.13, p.983181

2022

Volltextzugriff (PDF)

Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5‐year analysis of the French early access program (EPA)

British journal of haematology, 2022-07, Vol.198 (1), p.203-206

2022

Volltextzugriff (PDF)

A case of refractory IgG4-related disease successfully treated with daratumumab and lenalidomide

Rheumatology, 2024-08

2024

Volltextzugriff (PDF)

Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma

Clinical lymphoma, myeloma and leukemia, 2021-06, Vol.21 (6), p.e545-e547

2021

Volltextzugriff (PDF)

1 – 25 von 194

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(183)
Mit Volltextzugriff
(168)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(80)
Science & Technology
(80)
Hematology
(56)
Humans
(55)
Life Sciences
(54)
Male
(29)
Aged
(26)
Female
(26)
Middle Aged
(26)
Oncology
(24)
Adult
(19)
Cancer
(19)
Human Health And Pathology
(18)
Aged, 80 And Over
(13)
Patients
(11)
Retrospective Studies
(11)
Multiple Myeloma
(10)
Immunotherapy
(9)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(9)
Lymphoma
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A20 Gene Deregulation In Waldenstrom's Macroglobulinemia

ABCL-183 Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin (COO) in the POLARIX Study

Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy

Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): Evolution on hypomethylating agent therapy

Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma

Anti‐PD‐1 therapy can possibly reverse CAR T cells exhaustion in DLBCL

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA

B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenström Macroglobulinemia

B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenström Macroglobulinemia

BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia

Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study

Bendamustine is effective in T‐Cell prolymphocytic leukaemia

Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)

The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry

Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5‐year analysis of the French early access program (EPA)

A case of refractory IgG4-related disease successfully treated with daratumumab and lenalidomide

Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma

Suchergebnisse filtern